Digitala Vetenskapliga Arkivet

Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Biorelevant intrinsic dissolution profiling in early drug development: Fundamental, methodological, and industrial aspects
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Farmaceutiska fakulteten, Institutionen för farmaci.ORCID-id: 0000-0002-8917-2612
PION Inc, Forest Row Business Pk, Forest Row RH18 5DW, E Sussex, England.
Johnson & Johnson, Janssen R&D, Drug Prod Dev, Turnhoutseweg 30, B-2340 Beerse, Belgium.
GlaxoSmith Kline Med Res Ctr, Dept Prod Dev, 2G118,Gunnels Wood Rd, Stevenage, Herts, England.
Vise andre og tillknytning
2019 (engelsk)Inngår i: European journal of pharmaceutics and biopharmaceutics, ISSN 0939-6411, E-ISSN 1873-3441, Vol. 139, s. 101-114Artikkel, forskningsoversikt (Fagfellevurdert) Published
Abstract [en]

Intrinsic dissolution rate (IDR) is the surface specific dissolution rate of a drug. In early drug development, this property (among other parameters) is measured in order to compare different polymorphs and salt forms, guide formulation decisions, and to provide a quality marker of the active pharmaceutical ingredient (API) during production. In this review, an update on different methods and small-scale techniques that have recently evolved for determination of IDR is provided. The importance of biorelevant media and the hydrodynamic conditions of dissolution are also discussed. Different preparation techniques for samples are presented with a focus on disc, particle- and crystal-based methods. A number of small-scale techniques are then described in detail, and their applicability domains are identified. Finally, an updated industrial perspective is provided about IDR's place in the early drug development process.

sted, utgiver, år, opplag, sider
Elsevier, 2019. Vol. 139, s. 101-114
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-386370DOI: 10.1016/j.ejpb.2019.03.011ISI: 000468711400011PubMedID: 30862481OAI: oai:DiVA.org:uu-386370DiVA, id: diva2:1329101
Forskningsfinansiär
EU, FP7, Seventh Framework Programme, 115369Tilgjengelig fra: 2019-06-24 Laget: 2019-06-24 Sist oppdatert: 2019-06-24bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Bergström, ChristelTeleki, Alexandra
Av organisasjonen
I samme tidsskrift
European journal of pharmaceutics and biopharmaceutics

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 99 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf